CN101939028A - 针对蛋白酪氨酸激酶7(ptk7)的单克隆抗体伴侣分子偶联物 - Google Patents

针对蛋白酪氨酸激酶7(ptk7)的单克隆抗体伴侣分子偶联物 Download PDF

Info

Publication number
CN101939028A
CN101939028A CN200880118641XA CN200880118641A CN101939028A CN 101939028 A CN101939028 A CN 101939028A CN 200880118641X A CN200880118641X A CN 200880118641XA CN 200880118641 A CN200880118641 A CN 200880118641A CN 101939028 A CN101939028 A CN 101939028A
Authority
CN
China
Prior art keywords
antibody
seq
human
variable region
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN200880118641XA
Other languages
English (en)
Chinese (zh)
Inventor
J·A·特雷特
C·潘
C·拉奥-奈克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of CN101939028A publication Critical patent/CN101939028A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6819—Plant toxins
    • A61K47/6825—Ribosomal inhibitory proteins, i.e. RIP-I or RIP-II, e.g. Pap, gelonin or dianthin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Botany (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN200880118641XA 2007-11-30 2008-11-26 针对蛋白酪氨酸激酶7(ptk7)的单克隆抗体伴侣分子偶联物 Pending CN101939028A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US503407P 2007-11-30 2007-11-30
US61/005,034 2007-11-30
PCT/US2008/084949 WO2009073546A2 (en) 2007-11-30 2008-11-26 Monoclonal antibody partner molecule conjugates directed to protein tyrosine kinase 7 (ptk7)

Publications (1)

Publication Number Publication Date
CN101939028A true CN101939028A (zh) 2011-01-05

Family

ID=40718460

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200880118641XA Pending CN101939028A (zh) 2007-11-30 2008-11-26 针对蛋白酪氨酸激酶7(ptk7)的单克隆抗体伴侣分子偶联物

Country Status (11)

Country Link
US (1) US20120027782A1 (https=)
EP (1) EP2229187A2 (https=)
JP (1) JP2011505146A (https=)
KR (1) KR20100101124A (https=)
CN (1) CN101939028A (https=)
AR (1) AR069903A1 (https=)
AU (1) AU2008334076A1 (https=)
CL (1) CL2008003527A1 (https=)
MX (1) MX2010005966A (https=)
TW (1) TW200938223A (https=)
WO (1) WO2009073546A2 (https=)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103547597A (zh) * 2011-02-18 2014-01-29 施特姆森特Rx股份有限公司 新型调节剂及使用方法
US9777070B2 (en) 2014-04-30 2017-10-03 Pfizer Inc Anti-PTK7 antibody-drug conjugates
CN110845480A (zh) * 2019-11-22 2020-02-28 荣昌生物制药（烟台）有限公司 一种双功能细胞毒素及其用途
WO2023020551A1 (zh) * 2021-08-18 2023-02-23 和迈生物科技有限公司 抗ptk7单域抗体及其应用
WO2024222384A1 (zh) * 2023-04-26 2024-10-31 上海麦科思生物医药有限公司 抗ptk7抗体及其用途

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA017812B1 (ru) 2005-12-08 2013-03-29 Медарекс, Инк. Выделенное моноклональное антитело или его антигенсвязывающий участок, которые связываются с протеинтирозинкиназой 7 ( ptk7) человека, и их применение
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
ES2647317T3 (es) 2008-11-03 2017-12-20 Syntarga B.V. Análogos de CC-1065 y sus conjugados
PT3056203T (pt) 2010-04-21 2018-02-15 Syntarga Bv Conjugados de análogos de cc-1065 e ligantes bifuncionais
EP2380909A1 (en) * 2010-04-26 2011-10-26 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. PTK-7 protein involved in breast cancer
US8852599B2 (en) * 2011-05-26 2014-10-07 Bristol-Myers Squibb Company Immunoconjugates, compositions for making them, and methods of making and use
AU2012296951B2 (en) * 2011-08-12 2016-09-15 Ascendis Pharma A/S Protein carrier-linked prodrugs
UY34887A (es) 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
KR102442906B1 (ko) 2013-12-19 2022-09-14 씨젠 인크. 표적화된-약물 컨쥬게이트와 함께 사용되는 메틸렌 카바메이트 링커
RU2680404C2 (ru) 2014-01-10 2019-02-21 Синтон Байофармасьютикалс Б. В. Способ очистки cys-связанных конъюгатов антитело-лекарственное средство
PE20170441A1 (es) 2014-06-06 2017-04-26 Bristol Myers Squibb Co Anticuerpos contra el receptor del factor de necrosis tumoral inducido por glucocorticoides (gitr) y sus usos
AU2015349878A1 (en) 2014-11-21 2017-05-25 Bristol-Myers Squibb Company Antibodies against CD73 and uses thereof
JP6668345B2 (ja) 2014-11-21 2020-03-18 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 修飾された重鎖定常領域を含む抗体
JP6180663B2 (ja) 2014-12-23 2017-08-16 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｔｉｇｉｔに対する抗体
AU2016356780A1 (en) 2015-11-19 2018-06-28 Bristol-Myers Squibb Company Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof
EP3423494A1 (en) 2016-03-04 2019-01-09 Bristol-Myers Squibb Company Combination therapy with anti-cd73 antibodies
CA3051839A1 (en) 2017-02-17 2018-08-23 Bristol-Myers Squibb Company Antibodies to alpha-synuclein and uses thereof
CN110869392A (zh) 2017-05-16 2020-03-06 百时美施贵宝公司 用抗gitr激动性抗体治疗癌症
US20200299400A1 (en) 2017-05-25 2020-09-24 Bristol-Myers Squibb Company Antibodies comprising modified heavy constant regions
CN113260384A (zh) 2018-11-05 2021-08-13 西纳福克斯股份有限公司 用于靶向表达trop-2的肿瘤的抗体缀合物
US12605433B2 (en) 2020-07-16 2026-04-21 Uif (University Industry Foundation), Yonsei University Antibody specifically binding to PTK7 and use thereof
IL315366A (en) 2022-03-23 2024-11-01 Synaffix Bv Antibody pairs for targeting PTK7-expressing tumors
GB202212077D0 (en) 2022-08-18 2022-10-05 Tribune Therapeutics Ab Agents that inhibit ccn ligand-induced signalling for treating disease
US20260078201A1 (en) * 2022-09-06 2026-03-19 Uif (University Industry Foundation), Yonsei University Anti-ptk7 antibody, and use thereof
WO2025040588A1 (en) * 2023-08-18 2025-02-27 Oncoinvent As Monoclonal anti-ptk7 antibodies and derivatives
AR133955A1 (es) * 2023-09-26 2025-11-19 Profoundbio Us Co Agentes de unión a ptk7, conjugados de éstos y métodos de uso de los mismos

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1423110A4 (en) * 2001-09-07 2005-04-27 Scripps Research Inst CBI ANALOGUE OF CC-1065 AND DUOCARMYCINES
GB0219776D0 (en) * 2002-08-24 2002-10-02 Oxford Glycosciences Uk Ltd A protein involved in carcinoma
US7691962B2 (en) * 2004-05-19 2010-04-06 Medarex, Inc. Chemical linkers and conjugates thereof
JP4806680B2 (ja) * 2004-05-19 2011-11-02 メダレックス インコーポレイテッド 自己犠牲リンカー及び薬剤複合体
EP2354163A3 (en) * 2005-09-26 2013-04-24 Medarex, Inc. Conjugates of duocarmycin and anti-CD70 or anti-PSMA antibodies
EA017812B1 (ru) * 2005-12-08 2013-03-29 Медарекс, Инк. Выделенное моноклональное антитело или его антигенсвязывающий участок, которые связываются с протеинтирозинкиназой 7 ( ptk7) человека, и их применение

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103547597A (zh) * 2011-02-18 2014-01-29 施特姆森特Rx股份有限公司 新型调节剂及使用方法
US9409995B2 (en) 2011-02-18 2016-08-09 Stemcentrx, Inc. PTK7 modulators and methods of use
CN103547597B (zh) * 2011-02-18 2017-03-15 艾伯维施特姆森特克斯有限责任公司 新型调节剂及使用方法
CN107056945A (zh) * 2011-02-18 2017-08-18 艾伯维施特姆森特克斯有限责任公司 新型调节剂及使用方法
US9914784B2 (en) 2011-02-18 2018-03-13 Abbvie Stemcentrx Llc PTK7 modulators and methods of use
US10836831B2 (en) 2011-02-18 2020-11-17 Abbvie Stemcentrx Llc Anti-PTK7 antibodies and methods of use
US9777070B2 (en) 2014-04-30 2017-10-03 Pfizer Inc Anti-PTK7 antibody-drug conjugates
CN110845480A (zh) * 2019-11-22 2020-02-28 荣昌生物制药（烟台）有限公司 一种双功能细胞毒素及其用途
CN110845480B (zh) * 2019-11-22 2022-03-15 荣昌生物制药(烟台)股份有限公司 一种双功能细胞毒素及其用途
WO2023020551A1 (zh) * 2021-08-18 2023-02-23 和迈生物科技有限公司 抗ptk7单域抗体及其应用
WO2024222384A1 (zh) * 2023-04-26 2024-10-31 上海麦科思生物医药有限公司 抗ptk7抗体及其用途
US12534541B2 (en) 2023-04-26 2026-01-27 Mabcare Therapeutics Anti-PTK7 antibody and uses thereof

Also Published As

Publication number Publication date
EP2229187A2 (en) 2010-09-22
WO2009073546A2 (en) 2009-06-11
CL2008003527A1 (es) 2009-10-09
KR20100101124A (ko) 2010-09-16
WO2009073546A3 (en) 2009-12-30
AR069903A1 (es) 2010-03-03
TW200938223A (en) 2009-09-16
AU2008334076A1 (en) 2009-06-11
MX2010005966A (es) 2010-06-15
US20120027782A1 (en) 2012-02-02
JP2011505146A (ja) 2011-02-24

Similar Documents

Publication Publication Date Title
CN101939028A (zh) 针对蛋白酪氨酸激酶7(ptk7)的单克隆抗体伴侣分子偶联物
CA2700860C (en) Human antibodies that bind mesothelin, and uses thereof
JP5517626B2 (ja) Ｃｄ１９に結合するヒト抗体およびその使用
KR101552735B1 (ko) 씨디22에 결합하는 인간 항체 및 이의 용도
US9505845B2 (en) Treating lung cancer using human monoclonal antibodies to protein tyrosine kinase 7 (PTK7)
US20110085970A1 (en) Anti-b7h4 monoclonal antibody-drug conjugate and methods of use
US20100150950A1 (en) Human antibodies that bind cd70 and uses thereof
US20130156788A1 (en) Fully human antibodies specific to cadm1
CN101605906A (zh) 结合cd70的人类抗体及其用途
US20090162372A1 (en) Fibronectin ed-b antibodies, conjugates thereof, and methods of use
US20110020329A1 (en) Conjugates of anti-rg-1 antibodies
HK1140943B (en) Human antibodies that bind mesothelin, and uses thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20110105